source
- Argenx to acquire macrocycle biotech Unnatural Products in up to $1.15 billion dealArgenx announced Monday it will acquire Unnatural Products, a biotech focused on macrocycle therapeutics that began as a garage startup. The transaction is structured as an up-to-$1.15 billion dea…
- Phase II success does not guarantee easy Phase III launch, says Thermo FisherPositive Phase II data often signals the start of Phase III planning, but the transition involves far more than simply adding patients and sites. When a trial expands into new countries, differenc…